Long-Acting Injectable Drugs


Long-Acting Injectable Drugs  LONG-ACTING INJECTABLE DRUGS • LAD448F • December 2021 • US$3,850


 

 

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with less-frequent dosing.

Long-Acting injectable Drugs

 

 
 
 
 
     
 
 

 

What You Will Learn

• What are the marketed long-acting injectable drug products, what long-acting formulation technologies are used, and who markets them?
• What are the major factors driving long-acting injectable drug demand?
• What long-acting injectable drug candidates are in late-stage clinical development and what is their potential impact?
• How important are drug developer-formulation technologist relationships in the long-acting market segment, and what are the key alliances in the industry?
• What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for long-acting injectable drug products?
• In what therapeutic market segments do long-acting injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?
• What are the significant economic, technology, and regulatory factors affecting the market for long-acting injectable drugs?

 

Sustained Release Injectable Drugs – Summary of Contents 

Executive Summary

Executive Summary
Long-Acting Injectable Drugs
Executive Summary
Injectable Drug Market Dynamics
The Trend toward Self-Administration

Injectable Drug Formulation Technology
Innovation in Injectable Device Designs
Therapeutic Demand Drivers

Market Factors
Patient Compliance
Ease of Use
Healthcare Regulations
Managed Care Initiatives
Competitive Landscape
Risk Factors

Formulation Technologies
Biodegradable Polymers
PEG
PLA/PLGA
Polyether ester
Long-Acting Injectable
Formulation Technologies
BEPO (MedinCell)
ChroniJect (Oakwood Laboratories/PharmaSophia)
CriticalMix (Critical Pharmaceuticals)
Depofoam (Pacira)
FluidCrystal (Camarus)
LinkeRx (Alkermes)
Medisorb (Alkermes)
Medusa (Recipharm/Avadel)
Nanocrystals (Alkermes)
Optisomes (Talon/Spectrum)
PolyActive (Octoplus)
Q-Sphera (Midatech Pharma)
SABER/SAIB (DURECT)
SynBiosys (Innocore)
TransCon (Ascendis)

Physical Process Control Methods
Supercritical Fluid
SCF for Nanoparticle Formulations
Formulplex (Supercritical Solutions)
Ferro SCF extraction of emulsions (SFEE)

Long-Acting Injectables – Development Factors
Formulation Factors
Stability
Administration Factors

Long-Acting Product Analysis
Aripiprazole
Aripiprazole lauroxil
Bupivacaine
Buprenorphine
Cytarabine
Cytarabine & Daunorubicin
Doxorubicin
Estradiol
Exenatide
Fluphenazine decanoate
Goserelin acetate
Granisetron
Interferon (1)
Interferon (2)
Interferon (3)
Interferon (4)
Irinotecan
Lanreotide acetate
Leuprolide
Leuprolide Depot
Medroxyprogesterone
Naltrexone
Octreotide acetate
Olanzapine Pamoate
Paliperidone palmitate
Pasireotide
Pegvaliase-pqpz
Risperidone
Testosterone
Triptorelin (1)
Triptorelin (2)
Triamcinolone acetonide
Vincristine sulfate
Glycemic Control
AB101 (Rezolute)
Hormone Deficiency
human Growth Hormone/ Ascendis Pharma
Addiction
CAM2038 (Camurus)
Pain Management
Posidur/Durect
Cardiology
Treprostinil/Ascendis Pharma
Neurology
Relday/Risperidone (DURECT/Zogenix)
Oncology
CAM2032 (Camurus)

Therapeutic Sector Analysis
Addiction
Glycemic Control
Infectious Disease
Hepatitis
Neurology
Schizophrenia
Bipolar Disorder
Oncology
Pain Management
Reproductive Health
Fertility
Endometriosis

Company Profiles